AR061263A1 - Metodo para tratar trastornos respiratorios - Google Patents

Metodo para tratar trastornos respiratorios

Info

Publication number
AR061263A1
AR061263A1 ARP070102454A ARP070102454A AR061263A1 AR 061263 A1 AR061263 A1 AR 061263A1 AR P070102454 A ARP070102454 A AR P070102454A AR P070102454 A ARP070102454 A AR P070102454A AR 061263 A1 AR061263 A1 AR 061263A1
Authority
AR
Argentina
Prior art keywords
respiratory disorders
treat respiratory
antibiotic
antibiotic drug
aerosol composition
Prior art date
Application number
ARP070102454A
Other languages
English (en)
Inventor
Hanumantharao Tatapudy
Syed M Shah
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38657254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR061263A1 publication Critical patent/AR061263A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para tratar trastornos respiratorios mediante el suministro de una composicion en aerosol de una droga antibiotica a los alvéolos pulmonares. La droga antibiotica comprende ZOSYN, piperacilina, Tazobactam o TYGACIL y es administrada por vía de un sistema SWIRLER que produce una composicion en aerosol líquida de la droga antibiotica en la cual el tamano de las gotas de antibiotico en el aerosol rondan de 1 a 3 micrometros o menos.
ARP070102454A 2006-06-07 2007-06-07 Metodo para tratar trastornos respiratorios AR061263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81167106P 2006-06-07 2006-06-07

Publications (1)

Publication Number Publication Date
AR061263A1 true AR061263A1 (es) 2008-08-13

Family

ID=38657254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102454A AR061263A1 (es) 2006-06-07 2007-06-07 Metodo para tratar trastornos respiratorios

Country Status (4)

Country Link
AR (1) AR061263A1 (es)
PE (1) PE20080712A1 (es)
TW (1) TW200815003A (es)
WO (1) WO2007145866A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102641249A (zh) * 2012-05-06 2012-08-22 江苏奥赛康药业股份有限公司 一种替加环素组合物的制备方法
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
AU2014227660B2 (en) 2013-03-15 2014-11-06 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9566399B1 (en) 2015-04-14 2017-02-14 Clempharma LLC Deep lung alveolar aerosol targeted drug delivery

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5611332A (en) * 1995-03-22 1997-03-18 Bono; Michael Aerosol inhalation device containing a rain-off chamber
JP2005525375A (ja) * 2002-03-05 2005-08-25 トランセイブ， インク． 生物活性物質をリポソーム又は脂質複合体内に封入する方法

Also Published As

Publication number Publication date
PE20080712A1 (es) 2008-05-22
TW200815003A (en) 2008-04-01
WO2007145866A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
AR061263A1 (es) Metodo para tratar trastornos respiratorios
HRP20201325T1 (hr) Uporaba kanabidiola u liječenju kompleksa tuberozne skleroze
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
AR109590A2 (es) Régimen posológico para inhibidores de comt
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
CO7190240A2 (es) Sistema para tratar infecciones pulmonares
CL2007002356A1 (es) Sistema de liberacion farmaceutica que comprende flibanserina y por lo menos un excipiente farmaceuticamentre aceptable; y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, del sueno y sexuales, entre otros.
AR113749A1 (es) Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
CL2008001966A1 (es) Composicion de disolucion oral que comprende lamotrigina,en forma de particulas con lamotrigina recubiertas con una capa para enmascarar el sabor y granulos que comprenden un desinfectante y un alcohol de azucar y/o un hidrato de carbono; metodo de preparacion;uso para tratar trastornos del humor y prevencion de ataques.
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
AR059359A1 (es) Formulaciones farmaceuticas que contienen pleconaril
ECSP099556A (es) Nuevos métodos
AR061262A1 (es) Metodo para tratar trastornos respiratorios uso de un antibiotico enla fabricacion de un aerosol y composicion de antibiotico en aerosol
AR045312A1 (es) Metodo que comprende la administracion nasal de xilitol a un mamifero no humano
AR091205A1 (es) Farmaco para prevenir y tratar la enfermedad renal poliquistica
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
BRPI0406674A (pt) Composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de um aditivo farmaceuticamente aceitável, método para o tratamento ou prevenção de dor aguda ou crÈnica, dispositivo para pulverização, e, processo para preparar uma composição
AR050903A1 (es) Metodo para la prevencion de trastornos tromboticos, embolicos y/o hemorragicos
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
UY31662A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.
CL2009000322A1 (es) Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros.
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
BR112018074434A2 (pt) composições farmacêuticas compreendendo safinamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure